+ Watch RGEN
on My Watchlist
A biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases of the central nervous system.
Repligen has risen twice in the last six months on settlements of patent disputes. Aside from that, the company appears to have little going for it. The pipeline seems dubious to me. Pancreatic duct evaluation is a pretty obscure corner of the MRI market and I don't see a lot of benefit from an additional expensive step that improves your sensitivity by only 20% in phase II trials. Uridine for bipolar disorder? This is an molecule that's been lying around for a long time, and I think if it had significant psychoactive capability someone would have put it to use before now. The protein A revenues are stagnant at best, and didn't justify a market cap of more than 100M before the patent settlements. I expect the cap to head back down to the 100M range once it becomes clear that revenues are not going to improve significantly due to the settlements.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions